

**Investor Contact:**

Robert G. Burrows  
Vice President, Investor Relations  
240-631-3280  
BurrowsR@ebsi.com

**Media Contact:**

Tracey Schmitt Lintott  
Senior Vice President, Global Public Affairs  
240-631-3394  
SchmittT@ebsi.com

**EMERGENT BIOSOLUTIONS TO RELEASE SECOND QUARTER 2016 FINANCIAL RESULTS AND CONDUCT A CONFERENCE CALL ON AUGUST 4, 2016**

**GAITHERSBURG, MD, July 21, 2016**—Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, August 4, 2016 at 5:00 pm (Eastern Time) to discuss the financial results for the second quarter of 2016, provide an update on the status of guidance, highlight recent business developments, and review the remaining 2016 operational goals.

This conference call can be accessed live by telephone or through Emergent’s website:

**Live Teleconference Information:**

Dial in number: **(855) 766-6521**  
International dial in: (262) 912-6157  
Passcode: **29444249**

**Live Webcast Information:**

Visit [www.emergentbiosolutions.com](http://www.emergentbiosolutions.com)  
and select the “[Investors](#)” section

*Pre-registering for the live call will expedite access and minimize hold times. You will be issued a passcode to bypass the operator and connect directly. To pre-register for the call, visit the following website: <http://edge.media-server.com/m/p/7wsyx2ie/lan/en>.*

A replay of the call can be accessed on Emergent’s website [www.emergentbiosolutions.com](http://www.emergentbiosolutions.com) under “[Investors](#).”

**About Emergent BioSolutions**

Emergent BioSolutions is a global specialty biopharmaceutical company dedicated to one simple mission—to protect and enhance life. We develop, manufacture, and deliver a portfolio of medical countermeasures for biological and chemical threats as well as emerging infectious diseases. We also develop and commercialize therapeutics and other specialty products for hospitals and clinics in the areas of hematology/oncology, transplantation, infectious diseases and autoimmune disorders. Through our work, we envision protecting and enhancing 50 million lives with our products by 2025. Additional information about the company may be found at [www.emergentbiosolutions.com](http://www.emergentbiosolutions.com). Follow us @emergentbiosolu.

###